Literature DB >> 12207178

TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy.

H Wajant1, K Pfizenmaier, P Scheurich.   

Abstract

TNF-related apoptosis-inducing ligand (TRAIL/APO-2L) is a typical member of the TNF ligand family that induces apoptosis by activating the death receptors TRAIL-R1 and TRAIL-R2. TRAIL has attracted great attention in recent years as a promising anti cancer reagent because recombinant soluble TRAIL derivatives induce apoptosis in a broad range of tumor cells but not or only rarely in non-transformed cells. In this review we will address the putative role of TRAIL in cancer treatment in the light of the emerging importance of TRAIL in tumor surveillance and discuss the molecular basis of the cooperation of TRAIL and chemotherapeutic drugs. In particular, we debate controversial data in the literature concerning the cytotoxicity of different TRAIL derivatives on primary human cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12207178     DOI: 10.1023/a:1020039225764

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  35 in total

1.  Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.

Authors:  Karen Bräutigam; Julia Biernath-Wüpping; Dirk O Bauerschlag; Constantin S von Kaisenberg; Walter Jonat; Nicolai Maass; Norbert Arnold; Ivo Meinhold-Heerlein
Journal:  J Cancer Res Clin Oncol       Date:  2010-09-29       Impact factor: 4.553

2.  Caspase-10 sensitizes breast carcinoma cells to TRAIL-induced but not tumor necrosis factor-induced apoptosis in a caspase-3-dependent manner.

Authors:  Ingo H Engels; Gudrun Totzke; Ute Fischer; Klaus Schulze-Osthoff; Reiner U Jänicke
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

3.  Glycogen synthase kinase-3β regulates tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis via the NF-κB pathway in hepatocellular carcinoma.

Authors:  Kai Fu; Huazheng Pan; Shihai Liu; Jing Lv; Zhaojun Wan; Jiao Li; Qing Sun; Jun Liang
Journal:  Oncol Lett       Date:  2015-10-13       Impact factor: 2.967

4.  Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.

Authors:  Federica Servida; Daniele Lecis; Cinzia Scavullo; Carmelo Drago; Pierfausto Seneci; Carmelo Carlo-Stella; Leonardo Manzoni; Elio Polli; Giorgio Lambertenghi Deliliers; Domenico Delia; Francesco Onida
Journal:  Invest New Drugs       Date:  2010-07-08       Impact factor: 3.850

Review 5.  The promise of TRAIL--potential and risks of a novel anticancer therapy.

Authors:  Ronald Koschny; Henning Walczak; Tom M Ganten
Journal:  J Mol Med (Berl)       Date:  2007-04-17       Impact factor: 4.599

6.  Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact.

Authors:  Heath A Elrod; Songqing Fan; Susan Muller; Georgia Z Chen; Lin Pan; Mourad Tighiouart; Dong M Shin; Fadlo R Khuri; Shi-Yong Sun
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

7.  An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.

Authors:  Martin Siegemund; Oliver Seifert; Maria Zarani; Tamara Džinić; Valentino De Leo; Doris Göttsch; Sabine Münkel; Meike Hutt; Klaus Pfizenmaier; Roland E Kontermann
Journal:  MAbs       Date:  2016-04-11       Impact factor: 5.857

8.  Methyl jasmonate induces apoptosis and pro-apoptotic autophagy via the ROS pathway in human non-small cell lung cancer.

Authors:  Mutian Zhang; Ling Su; Zhenna Xiao; Xianfang Liu; Xiangguo Liu
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

9.  Down-modulation of heat shock protein 70 and up-modulation of Caspase-3 during schisandrin B-induced apoptosis in human hepatoma SMMC-7721 cells.

Authors:  Yi-Feng Wu; Ming-Fu Cao; Yan-Ping Gao; Fei Chen; Tao Wang; Edward P Zumbika; Kai-Xian Qian
Journal:  World J Gastroenterol       Date:  2004-10-15       Impact factor: 5.742

Review 10.  TRAIL in cancer therapy: present and future challenges.

Authors:  Delphine Mérino; Najoua Lalaoui; Alexandre Morizot; Eric Solary; Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2007-10       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.